Efficacy News and Research

RSS

Government data underestimates the impact of social distancing in controlling COVID-19 spread

Quantifying the mitigating impact of social distancing on the spread of COVID-19 is critical for evaluating the efficacy of social restrictions and informing future health policy decisions.

11 Dec 2020

Researchers use AI platform to identify best combination of available therapies against COVID-19.

A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

11 Dec 2020

New survey to understand the prevalence of marijuana use among cancer patients

Marijuana use is illegal in South Carolina, even for medical purposes. But national survey data shows that the use of marijuana for medical reasons is common, regardless of whether the people who use it live in a state with a legal marketplace.

10 Dec 2020

Using AI to find optimal combination of available therapies against SARS-CoV-2

A team of researchers from the National University of Singapore has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

10 Dec 2020

Hydroxychloroquine found ineffective as post-exposure SARS-CoV-2 prophylaxis

Now, a study on the utility of hydroxychloroquine as prophylaxis against COVID-19, has been released in the latest issue of Annals of Internal Medicine.

10 Dec 2020

MEDS433 hinders SARS-CoV-2 replication

A paper that recently appeared in the preprint server bioRxiv* reports the powerful activity of a compound named MEDS433 against this virus.

10 Dec 2020

Takeda brings innovative pipeline portfolio to patients for sustained revenue growth

As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade.

From Takeda 10 Dec 2020

Interim analysis of phase 3 study shows excellent efficacy of SARS-CoV-2 vaccine

South African study data were used to evaluate the safety of the vaccine in the results just published, but not its efficacy [which refers to the percentage reduction of disease].

9 Dec 2020

Researchers examine how COVID-19 face masks can be made more effective

Face masks are helpful in preventing the spread of COVID-19, but researchers believe they can be made even more effective, something that has implications far beyond the current pandemic as masks could become a more commonly used public health intervention.

9 Dec 2020

Autistic children show significant IQ increases between the ages of 12 to 23 years

Individuals diagnosed with autism spectrum disorder (ASD) face a lifelong challenge characterized by qualitative impairments in both communication and social interaction.

9 Dec 2020

Virginia Tech researchers awarded NIH grant to develop Zika virus vaccine

Flaviviruses -- a group of viruses transmitted by ticks or mosquitoes -- infect an estimated 400 million people annually with diseases like yellow fever, Dengue fever, West Nile virus, and, most recently, Zika virus.

9 Dec 2020

UofL receives DoD funding to develop a nasal spray for preventing COVID-19

The University of Louisville has received funding from the U.S. Department of Defense (DoD) to develop a nasal spray to prevent serious viral respiratory infections such as COVID-19 using Q-Griffithsin, a drug compound developed and co-owned by UofL.

9 Dec 2020

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalizations or severe disease reported in the COVID-19 vaccine group so far.

9 Dec 2020

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

Efficacy News and Research

Government data underestimates the impact of social distancing in controlling COVID-19 spread

Researchers use AI platform to identify best combination of available therapies against COVID-19.

New survey to understand the prevalence of marijuana use among cancer patients

Using AI to find optimal combination of available therapies against SARS-CoV-2

Hydroxychloroquine found ineffective as post-exposure SARS-CoV-2 prophylaxis

MEDS433 hinders SARS-CoV-2 replication

Takeda brings innovative pipeline portfolio to patients for sustained revenue growth

Interim analysis of phase 3 study shows excellent efficacy of SARS-CoV-2 vaccine

Researchers examine how COVID-19 face masks can be made more effective

Autistic children show significant IQ increases between the ages of 12 to 23 years

Virginia Tech researchers awarded NIH grant to develop Zika virus vaccine

UofL receives DoD funding to develop a nasal spray for preventing COVID-19

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

Amilorides reduce SARS-CoV-2 viral replication in vitro

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Untangling the role of medical cannabis in surgical care

Research shows how targeted microbubbles can carry powerful cancer drugs

Bioactive tea compounds show potential anti-SARS-CoV-2 activity

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News